CHAPTERS
- 0:00 – 1:13
Mushroom felt hats: amadou, Otzi, and portable fire
Joe and Paul open by examining Paul’s mushroom felt hat made from Fomes fomentarius (amadou). Paul explains how this fungus was used historically for carrying embers, surviving cold migrations, and later as tinder for early firearms—linking fungi to major human technological shifts.
- •Hat material is amadou (“German felt”) made from birch polypore
- •Historical use: portable fire for days; survival advantage in winter climates
- •Otzi the Iceman connection and ancient travel in the Alps
- •Warfare link: helped flint-based ignition systems for gunpowder
- •Introduces birch polypore as a current research focus
- 1:13 – 4:02
How amadou becomes fabric: ash-water processing and felting
Paul walks through the practical process of turning a tough polypore conk into a pliable textile. They discuss alkaline ash-water soaking, delamination, pulling fibers into felt, durability, and fire risk—plus modern artisanal production in Transylvania.
- •Soaking in water + wood ash (alkaline) causes delamination
- •Mycelial layers can be pulled and repeatedly felted into fabric
- •Used for beekeeping smoke and as a slow-burning ‘fuse’ tinder
- •Natural colors and construction methods; strong but water-absorbing
- •Risk: fabric can ignite easily near fire or cigarettes
- 4:02 – 4:51
Preserving a vanishing craft: Transylvanian hat makers and how to buy
They shift from technique to cultural preservation—how the number of traditional hat makers dwindled and how orders helped keep the craft alive. Paul shares where listeners can find and purchase hats to support the remaining makers.
- •Hat-making industry shrank from dozens of makers to a few
- •Friends flagged the craft as near-extinction; orders revived demand
- •Small community of a few hundred wearers
- •How to find sellers via Paul’s social media presence
- •Transition: this mushroom’s importance goes beyond hats
- 4:51 – 8:57
Mushrooms and the bee ‘insect apocalypse’: antiviral discoveries and Nature paper
Paul outlines the scale of insect decline and introduces his team’s research showing mushroom mycelium extracts can drastically reduce bee viruses. He describes publishing results within the Nature ecosystem and explains the varroa mite/virus cascade harming colonies.
- •Insect decline framing: large-scale threat; ‘all hands on deck’
- •Nature Scientific Reports publication and its impact/visibility
- •Amadou extract reduces deformed wing virus ~800:1 in one treatment
- •Reishi mycelium reduces Lake Sinai virus ~45,000:1
- •Varroa mites act like ‘dirty syringes,’ injecting debilitating viruses
- 8:57 – 14:58
Citizen-science bee feeders: deployment, vertical ‘ecological ladders,’ and big-data monitoring
Paul presents a practical intervention: free bee feeders delivering mushroom extracts in sugar water, designed for widespread public participation. They discuss scaling via neighborhoods, vertical gardens, solar/wifi instrumentation, and building a global baseline dataset for pollination health.
- •Free giveaway and signup: fungi.com/bees
- •Feeder design encourages bee visits; video demo and ‘maze’ behavior
- •Concept: place feeders to support wild bees (major share of pollination)
- •Future instrumentation: solar, blue LEDs, counting bees, LTE/cloud upload
- •Goal: create global baselines and detect collapses early via metrics
- 14:58 – 18:02
Root causes of collapse: pesticides, monoculture ‘pollination deserts,’ and virus spread via flowers
The conversation digs into why bees and insects are disappearing: pesticides, habitat loss, factory farming, and viral pandemics spread through shared flowers. Paul explains how colony collapse can happen abruptly and why nurse-bee dynamics amplify mite/virus impacts.
- •Drivers: pesticides, glyphosate, pollution, habitat loss, monoculture
- •Monoculture creates seasonal food gaps (‘pollination deserts’)
- •Viruses spread globally; infected bees leave viral particles on flowers
- •Colony collapse can occur in days with bees simply ‘gone’
- •Nurse bees recruited early; brood abandoned; mites and infections cascade
- 18:02 – 22:30
Cellphone hypothesis, bee behavior stories, and research design nuances
Joe asks about cellphones as a contributing factor; Paul stays cautious and calls for stronger data. They share anecdotes about bee communication and discuss ‘bee drift’ between colonies that can dilute experimental differences—yet the results remain statistically strong.
- •Cellphone radiation remains a hypothesis; Paul is unconvinced without data
- •Fear Factor bee-swarm anecdote: colonies ‘work it out’ in the air
- •Bee drift (10–20%) can blur treatment vs control comparisons
- •Despite drift, p-values show strong significance in published results
- •Mode-of-action hypothesis: nutrients trigger immune gene activation
- 22:30 – 25:11
From bee immunity to human health: translational medicine and the case for complex natural products
Paul argues the bee findings support a broader view: complex natural mixtures can provide wider ‘bioshields’ than single-target pharmaceuticals. He introduces physician-facing resources and stresses that clinical evidence for medicinal mushrooms is rapidly expanding.
- •Bee study framed as an animal clinical model with digestion and systemic effects
- •Critique of single-molecule, single-target pharma vs complex immune systems
- •mushroomreferences.com as a clinician-focused database of studies
- •Growing clinical interest in reishi, chaga, and related medicinal fungi
- •Positions psilocybin research as a major area of focus
- 25:11 – 27:56
Psilocybin enters mainstream science: universities, PTSD/addiction outcomes, and microdosing potential
They review the rapid legitimation of psilocybin research across major institutions and highlight notable results such as tobacco cessation. Paul expands into microdosing as a tool for creativity, cognition, and solving societal-scale problems.
- •Many universities/VA programs now approved for psilocybin clinical studies
- •Johns Hopkins tobacco study: 10/15 abstinent at 12 months after 1–2 high doses
- •Applications discussed: PTSD, depression, addiction, cognition, creativity
- •Microdosing framed as scalable societal benefit to innovate solutions
- •Concern: ‘too good to be true’ data volume—need better measurement and datasets
- 27:56 – 30:58
microdose.me app: building baselines, cognitive tests, and finding signals in big data
Paul announces an app to standardize self-tracking for microdosing (and non-psychoactive baselines), measuring performance markers and enabling large datasets for clinicians. They discuss hypotheses like tinnitus improvement and the creativity–happiness feedback loop.
- •App launch: microdose.me (iOS/Android) and why App Store approval matters
- •Measures: hearing/vision, reaction/tap tests, baselines over time
- •Goal: massive dataset to help clinicians extract ‘signal from noise’
- •Hypothesis: microdosing may help tinnitus/hearing-related decline in some cases
- •Creativity and happiness reinforce each other; microdosing as catalyst
- 30:58 – 36:43
Microdosing vs macrodosing: mouse fear-conditioning study and competing protocols
Paul describes a mouse study suggesting microdosing may reduce conditioned fear faster than higher doses, connecting it to potential PTSD mechanisms and neurogenesis. He compares the Fadiman protocol with the Stamets protocol and argues for broader outcome testing beyond mood scores.
- •Mouse study: tone-shock conditioning; microdose reduced fear response in ~2 cycles vs ~10
- •Hypothesis: microdosing may promote more sustained neurogenesis than receptor ‘flooding’ trips
- •Call for objective measures (hearing/vision/behavior) pre- and post-session
- •Protocols: Fadiman (1 day on, 2 off) vs Stamets (4 on, 3 off)
- •Need comparative data—app intended to help evaluate protocols/stacking choices
- 36:43 – 51:45
Psilocybin analogs, baeocystin self-experiment, and the ‘stack’ with lion’s mane + niacin
Paul recounts an N-of-1 bioassay of baeocystin—legal psilocybin analog—reporting reduced anxiety without intoxication. He argues the future may involve standardized natural mixtures and describes his microdosing ‘stack’ rationale, including niacin as an anti-abuse and delivery mechanism.
- •Explains psilocybin analogs (baeocystin/norbaeocystin) and legality distinctions
- •Baeocystin origin story and why it was suspected as a toxin historically
- •N-of-1: 10 mg baeocystin reduced acute anxiety; no ‘liftoff’ psychedelic effect
- •Advocates exploring analogs and whole-mushroom complexity vs pure psilocybin cost barrier
- •Microdosing stack: psilocybin + niacin (anti-abuse flush, vasodilation, nerve-end stimulation) + lion’s mane for neurogenesis
- 51:45 – 1:08:17
Legalization and the cultural shift: decriminalization, ‘Spore Wars,’ and Fantastic Fungi
They move to policy and culture—Oakland/Denver decriminalization models, tensions around sale vs possession, and the rise of commercial ‘economic opportunists.’ Paul promotes the documentary Fantastic Fungi as a grassroots catalyst and discusses the mainstream rebrand of psychedelics.
- •Decriminalization mechanics: deprioritizing prosecution funding (Oakland/Denver)
- •Debate: personal use vs trafficking; responsibility and legal gray zones
- •Rise of psilocybin startups; concern about profiteers who haven’t experienced the medicine
- •Fantastic Fungi release strategy (theaters/community) and its role in awareness
- •Joe and Paul reflect on stigma fading and mainstream acceptance accelerating
- 1:08:17 – 1:22:24
Safety, responsibility, and who should not take psychedelics: schizophrenia risk and set/setting
Joe raises mental health risks, especially schizophrenia vulnerability and cannabis-triggered breaks, and Paul agrees caution is warranted while deferring to clinicians. They emphasize dosage, individual variability, responsible frameworks (sitters/therapists), and the importance of structured support.
- •Clinical studies screen out candidates with schizophrenia risk factors
- •Cannabis (especially high-dose edibles/concentrates) discussed as trigger for some
- •Dose matters; individual responses vary widely
- •Set/setting: sitters, nature-based contexts, and preparation for challenging experiences
- •Emerging training programs for psychedelic therapists; clinics worldwide
- 1:22:24 – 1:36:48
Medicinal mushrooms deep dive: lion’s mane neurogenesis, mycelium vs fruiting bodies, and microbiome effects
They pivot to non-psychedelic functional mushrooms—especially lion’s mane—covering evidence for neurite outgrowth and synergy with psilocybin analogs. Paul argues mycelium often contains more active immune-related compounds than fruiting bodies and connects fungi to soil carbon storage and human gut health.
- •Lion’s mane: mycelium shown more neuroactive than fruiting body in tests
- •In vitro data: neurite outgrowth increases; synergy when stacked with legal analogs
- •Explains dilution/titration findings and pharmacokinetic considerations
- •Mycelium biology: immune-active in natural temperature window; extensive soil networks
- •Turkey tail as prebiotic; supports beneficial bacteria and suppresses inflammatory Clostridium
- 1:36:48 – 1:48:54
Cordyceps complexity, product quality, and Host Defense research approach
Paul explains why Cordyceps sinensis research is taxonomically messy due to multiple fungi co-occurring, and suggests Cordyceps militaris as a cleaner choice. They discuss sourcing, labeling mycelium vs fruiting body, athletic use, and Paul’s company (Host Defense) as a research-driven operation.
- •Cordyceps sinensis (Ophiocordyceps) confusion: multiple fungi ‘chasing’ within specimens
- •Many past studies now ‘suspect’ due to unclear organism/animorph used
- •Recommendation: prefer Cordyceps militaris for clarity
- •Quality controls: chain of custody; ensure labels specify mycelium vs fruit body
- •Host Defense/fungi.com; research staffing, patents, and species-by-species validation
- 1:48:54 – 1:59:55
Amanita warnings and the pantherina horror story: legality doesn’t mean safety
Paul shares intense experiences with Amanita muscaria and especially Amanita pantherina, emphasizing dangerous effects like repetitive motion syndrome, temporary insanity, convulsions, and hypothermia risk. The segment serves as a strong harm-reduction contrast to psilocybin’s typical profile.
- •Amanita muscaria: muscimol/ibotenic acid; unpleasant muscarinic effects possible
- •Amanita pantherina described as far more potent and behaviorally hazardous
- •Story: impaired judgment, repetitive motion syndrome, damaged camera, public panic
- •Convulsions and altered thought loops; danger of exposure/hypothermia
- •Recommendation: do not use; legal status is not a safety indicator
- 1:59:55 – 2:06:57
Mushrooms, religion, and lasting psychological benefits: re-remembering and clinical spirituality outcomes
They discuss claims linking mushrooms to religious traditions and art, with Paul acknowledging influence while rejecting overconfident historical conclusions. He highlights Johns Hopkins findings on mystical experiences, lasting positive personality change, and the idea that recalling profound sessions may help overwrite trauma responses.
- •Evaluates Sacred Mushroom & the Cross claims with skepticism but openness to influence
- •Examples of religious communities using psilocybin sacramentally
- •Hindu/cow/cubensis speculation and gatekeeping of powerful knowledge
- •Johns Hopkins: many report among most spiritually significant life experiences
- •‘Re-remembering’ as a mechanism: positive anchor memories may counter PTSD patterns
- 2:06:57 – 2:12:08
Where this is headed: therapy centers, global momentum, and closing reflections
They close by noting that guided psychedelic therapy training is already underway and that legalization trends are moving steadily forward. Paul stresses psilocybin’s anti-addictive nature, responsible use, and community-minded leadership as the movement scales.
- •Psychedelic therapy training programs emerging (US/Canada/Europe)
- •International clinics in legal jurisdictions (Portugal, Jamaica, Mexico, etc.)
- •Psilocybin framed as ‘anti-addictive’ due to profundity and spacing of use
- •Community responsibility: help people who go off-rails rather than judge
- •Final resources: fungi.com and films Fantastic Fungi and Dosed
